| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.3 | 0.02 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.64 | 0.02 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |